The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies

Drug Resist Updat. 2022 Dec:65:100882. doi: 10.1016/j.drup.2022.100882. Epub 2022 Oct 3.

Abstract

WHO-defined SARS-CoV-2 variants of concern (VOC) drive therapeutics and vaccine development. The Omicron VOC is dominating the arena since November 2021, but the number of its sublineages is growing in complexity. Omicron represent a galaxy with a myriad of stars that suddenly rise and expand before collapsing into apparent extinction when a more fit sublineage appears. This has already happened with BA.1, BA.2, and BA.4/5 and is happening with BA.2.75. We review here the current PANGO phylogeny, focusing on sublineages with Spike mutations, and show how frequently xxxxxxxx convergent evolution has occurred in these sublineages. We finally summarize how Omicron evolution has progressively defeated the anti-Spike monoclonal antibodies authorized so far, leaving clinicians to again fall back on COVID19 convalescent plasma from vaccinated donors as the only antibody-based therapy available.

Keywords: B.1.1.529; BA.1; BA.2; BA.2.12.1; BA.2.75; BA.4; BA.4.6; BA.5; Omicron; SARS-CoV-2; Spike; VOC; Variant of concern.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / genetics
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antineoplastic Agents, Immunological*
  • COVID-19 Serotherapy
  • COVID-19*
  • Humans
  • SARS-CoV-2 / genetics
  • Spike Glycoprotein, Coronavirus / genetics

Substances

  • Antibodies, Monoclonal
  • spike protein, SARS-CoV-2
  • Spike Glycoprotein, Coronavirus
  • Antineoplastic Agents, Immunological
  • Antibodies, Viral
  • Antibodies, Neutralizing

Supplementary concepts

  • SARS-CoV-2 variants